相关实验视频

Updated: May 11, 2025

Generation and Expansion of Human Cardiomyocytes from Patient Peripheral Blood Mononuclear Cells

Generation and Expansion of Human Cardiomyocytes from Patient Peripheral Blood Mononuclear Cells

Published on: February 12, 2021

用于临床应用的iPSC衍生的心肌细胞的生成和净化

M Generali¹, D Kehl², D Meier²

¹Institute for Regenerative Medicine, University of Zurich, Zurich, Switzerland. melanie.generali@uzh.ch.

Stem cell research & therapy

|April 18, 2025

概括

这项研究详细介绍了从诱导多能干细胞 (iPSCs) 中产生临床级心肌细胞 (iCMs) 的方法,用于心脏组织修复. 这些安全,纯粹的ICM为心肌梗塞提供了有前途的细胞疗法.

科学领域:

再生医学是一种再生医学.
心血管研究研究心血管研究
干细胞生物学干细胞生物学

背景情况:

细胞疗法在组织修复方面取得了进展,但对心肌梗塞的有效治疗仍然有限.
目前的选择无法再生心脏病发作后丢失的心脏组织.
需要新的治疗策略来治疗心肌梗塞.

研究的目的:

为了产生临床级心肌细胞 (iCMs),用于潜在的心肌梗塞治疗.
为安全的临床应用制定适应ICM的协议.
建立无外基因和无转基因的细胞疗法解决方案.

主要方法:

从转基因和无外基因诱导的多能干细胞 (iPSCs) 生成符合良好制造实践 (GMP) 的心肌细胞 (iCMs).
在无毒素条件下对iCM进行复制和冷保存的既定协议.
利用RNA-switch技术确保纯的iCM群体,并最大限度地降低iPSC污染风险.

主要成果:

生成的iCMs表现出明显的心脏表型,由特定的心脏标记物表达证实.
在RNA和蛋白质水平上都缺少多能性标记物,这表明成功分化.
转换RNA技术有效地降低了iCM群体残留iPSC污染的风险.

结论:

成功生成和加工适合临床使用的无外基因和无转基因ICM.
符合GMP的差异化协议对于iCM治疗的无临床转化至关重要.
这项工作为推进基于细胞的心脏修复疗法提供了基础.

关键词:

心脏肌细胞是心脏肌细胞.细胞疗法是一种细胞疗法.临床翻译临床翻译诱导的多能干细胞干细胞

更多相关视频

Generation of Ventricular-Like HiPSC-Derived Cardiomyocytes and High-Quality Cell Preparations for Calcium Handling Characterization

Generation of Ventricular-Like HiPSC-Derived Cardiomyocytes and High-Quality Cell Preparations for Calcium Handling Characterization

Published on: January 17, 2020

Fabrication of 3D Cardiac Microtissue Arrays using Human iPSC-Derived Cardiomyocytes, Cardiac Fibroblasts, and Endothelial Cells

Fabrication of 3D Cardiac Microtissue Arrays using Human iPSC-Derived Cardiomyocytes, Cardiac Fibroblasts, and Endothelial Cells

Published on: March 14, 2021

相关概念视频

Induced Pluripotent Stem Cells

Induced Pluripotent Stem Cells

Stem cells are undifferentiated cells that divide and produce different types of cells. Ordinarily, cells that have differentiated into a specific cell type are post-mitotic—that is, they no longer divide. However, scientists have found a way to reprogram these mature cells so that they “de-differentiate” and return to an unspecialized, proliferative state. These cells are also pluripotent like embryonic stem cells—able to produce all cell types—and are therefore...

iPS Cell Differentiation

iPS Cell Differentiation

The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.

EPS and iPS Cells in Disease Research

EPS and iPS Cells in Disease Research

Embryonic and induced pluripotent stem cells are excellent models for disease research because of their ability to self-renew and differentiate into most cell types. Somatic cells from a patient are isolated and reprogrammed into induced pluripotent stem cells or iPSCs. These iPSCs are later differentiated into the desired cell type, which mirrors the diseased cell of the patient. In this way, disease models have been created for investigating diseases such as Down syndrome, type I diabetes,...